Monday, 5 October 2009

Benzyl Benzoate




In some countries, this medicine may only be approved for veterinary use.

Scheme

USP

ATC (Anatomical Therapeutic Chemical Classification)

P03AX01

CAS registry number (Chemical Abstracts Service)

0000120-51-4

Chemical Formula

C14-H12-O2

Molecular Weight

212

Therapeutic Category

Scabicide

Chemical Name

Benzoic acid, phenylmethyl ester

Foreign Names

  • Benzylis benzoas (Latin)
  • Benzyl benzoat (German)
  • Benzoate de benzyle (French)

Generic Names

  • Acarobenzyl (IS)
  • Benzevan (IS)
  • Benzoesäurebenzylester (IS)
  • Spasmodine (IS)
  • Benzyl Benzoate (PH: BP 2010, Ph. Eur. 6, Ph. Int. 4, USP 32, JP XV)
  • Benzylbenzoat (PH: Ph. Eur. 6)
  • Benzyle (benzoate de) (PH: Ph. Eur. 6)
  • Benzylis benzoas (PH: Ph. Int. 4, Ph. Eur. 6)

Brand Names

  • Acaril
    Medifarma, Peru


  • Acarilbial
    Bial, Portugal


  • Acarsan
    Biosintética, Brazil


  • Antiscabiosum
    Strathmann, Germany


  • Antiscabiosum für Kinder (pediatric)
    Strathmann, Germany


  • Ascabiol
    Aspen Pharmacare Consumer, South Africa; Sanofi-Aventis, Australia; Sanofi-Aventis, Bangladesh


  • Ascabiol (Benzyl Benzoate and Sulfiram)
    Zambon, France


  • Ascalol
    Pharmaghreb, Tunisia


  • B.B. Lotion
    Washington Pharm, Taiwan


  • Benciderm
    Roxfarma, Peru


  • Benosol
    Amico, Bangladesh


  • Benzalcor
    Corsalud, Venezuela


  • Benzalcort
    SM Pharma, Venezuela


  • Benzibel
    Luper, Brazil


  • Benzil benzoat Jadran
    Jadran, Croatia (Hrvatska)


  • Benzoat de Benzil
    Mark, Romania


  • Benzoato de bencilo MK
    McKesson, Ecuador; MK, Colombia


  • Benzoato de bencilo
    Etyc, Colombia; Pentacoop, Colombia; Pifano, Venezuela; Roxfarma, Peru


  • Benzogal
    Rafarm, Greece


  • Benzotal
    Tallinna, Latvia


  • Benzyl Benzoate
    ACPC - Arab Center for Pharmaceutical and Chemical, Oman; Bell, Bahrain; Bell's, Malta; Hoe Pharmaceuticals, Ethiopia; IFET, Greece; Rusichi, Georgia; Thornton & Ross, Malta


  • Benzylbenzoat
    Grindex, Georgia; TFT, Estonia


  • Benzylbenzoate
    Nizhpharm, Russian Federation


  • Cabisol
    Chemist, Bangladesh


  • Carr & Day & Martin Killitch (veterinary use)
    Quay Equestrian, United Kingdom


  • Finsarna
    Qualicont, Peru


  • Gensarna
    Gencopharmaceutical, Peru


  • Hastilan
    Continentales, Mexico


  • Killitch (veterinary use)
    Carr & Day & Martin, United Kingdom


  • Miticocan
    Aché, Brazil


  • Novoscabin
    Polon, Poland


  • Opele
    Beta Health Care, Ethiopia; The Boots Company, Ethiopia


  • Prurivet (Benzyl Benzoate and Chloramphenicol, + Dexamethasone (veterinary use))
    Vetochas, Germany; Vetoquinol, Austria


  • Prurivet N (Benzyl Benzoate and Chloramphenicol, + Dexamethasone (veterinary use))
    Vetoquinol, Switzerland


  • Saniscabis
    Neo-Fármaco, Ecuador


  • Sarnacur
    Laser, Peru


  • Scabicon
    Medicon, Bangladesh


  • Scabiex
    Rekah, Israel


  • Scabin
    Abdi Ibrahim, Turkey


  • Scabisol
    Jayson, Bangladesh


  • Scabitox
    Bosnalijek, Bosnia & Herzegowina


  • Sweet Itch Plus (veterinary use)
    Pettifer, United Kingdom


  • Tenutex (Benzyl Benzoate and Disulfiram)
    Bioglan, Sweden

International Drug Name Search

Glossary

ISInofficial Synonym
PHPharmacopoeia Name
USPPharmacopoeia of the United States

Click for further information on drug naming conventions and International Nonproprietary Names.

Sunday, 27 September 2009

Colcrys


Colcrys is a brand name of colchicine, approved by the FDA in the following formulation(s):


COLCRYS (colchicine - tablet; oral)



  • Manufacturer: AR HOLDING CO INC

    Approval date: July 29, 2009

    Strength(s): 0.6MG [RLD]

Has a generic version of Colcrys been approved?


No. There is currently no therapeutically equivalent version of Colcrys available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Colcrys. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
    Patent 7,601,758
    Issued: October 13, 2009
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for treating gout flares comprising concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.
    Patent expiration dates:

    • February 10, 2029
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES




  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 7,619,004
    Issued: November 17, 2009
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.
    Patent expiration dates:

    • December 3, 2028
      ✓ 
      Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES




  • Methods for concomitant administration of colchicine and a second active agent
    Patent 7,820,681
    Issued: October 26, 2010
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:

    • February 17, 2029
      ✓ 
      Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES




  • Methods for concomitant administration of colchicine and a second active agent
    Patent 7,906,519
    Issued: March 15, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): AR Holding Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:

    • February 17, 2029
      ✓ 
      Patent use: METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS




  • Methods for concomitant administration of colchicine and a second active agent
    Patent 7,915,269
    Issued: March 29, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): AR Holding Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:

    • February 17, 2029
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES




  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 7,935,731
    Issued: May 3, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
    Patent expiration dates:

    • December 3, 2028
      ✓ 
      Patent use: METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS




  • Colchicine compositions and methods
    Patent 7,964,647
    Issued: June 21, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
    Patent expiration dates:

    • October 6, 2028
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES




  • Methods for concomitant administration of colchicine and a second active agent
    Patent 7,964,648
    Issued: June 21, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:

    • October 6, 2028
      ✓ 
      Patent use: FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER




  • Colchicine compositions and methods
    Patent 7,981,938
    Issued: July 19, 2011
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
    Patent expiration dates:

    • October 6, 2028
      ✓ 
      Patent use: A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS




  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 8,093,296
    Issued: January 10, 2012
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
    Patent expiration dates:

    • October 6, 2028
      ✓ 
      Patent use: METHOD OF TREATING GOUT FLARES




  • Methods for concomitant administration of colchicine and a second active agent
    Patent 8,093,297
    Issued: January 10, 2012
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Patent expiration dates:

    • October 6, 2028
      ✓ 
      Patent use: FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER




  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 8,093,298
    Issued: January 10, 2012
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
    Patent expiration dates:

    • October 6, 2028
      ✓ 
      Patent use: METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS




  • Methods for concomitant administration of colchicine and macrolide antibiotics
    Patent 8,097,655
    Issued: January 17, 2012
    Inventor(s): Davis; Matthew W.
    Assignee(s): Mutual Pharmaceutical Company, Inc.
    Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
    Patent expiration dates:

    • October 6, 2028
      ✓ 
      Patent use: METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 30, 2012 - GOUT FLARES

    • July 29, 2016 - ORPHAN DRUG EXCLUSIVITY

See also...

  • Colcrys Consumer Information (Drugs.com)
  • Colcrys Consumer Information (Wolters Kluwer)
  • Colcrys Consumer Information (Cerner Multum)
  • Colcrys Advanced Consumer Information (Micromedex)
  • Colcrys AHFS DI Monographs (ASHP)
  • Colchicine Consumer Information (Wolters Kluwer)
  • Colchicine Consumer Information (Cerner Multum)
  • Colsalide Advanced Consumer Information (Micromedex)
  • Colchicine Oral, Intravenous Advanced Consumer Information (Micromedex)
  • Colchicine AHFS DI Monographs (ASHP)

Saturday, 26 September 2009

Moxacil




Moxacil may be available in the countries listed below.


Ingredient matches for Moxacil



Amoxicillin

Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Moxacil in the following countries:


  • Bangladesh

  • Sri Lanka

International Drug Name Search

Alcool benzilico




Alcool benzilico may be available in the countries listed below.


Ingredient matches for Alcool benzilico



Benzyl Alcohol

Alcool benzilico (DCIT) is known as Benzyl Alcohol in the US.

International Drug Name Search

Glossary

DCITDenominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.

Thursday, 24 September 2009

Vindésine




Vindésine may be available in the countries listed below.


Ingredient matches for Vindésine



Vindesine

Vindésine (DCF) is known as Vindesine in the US.

International Drug Name Search

Glossary

DCFDénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Belepar




Belepar may be available in the countries listed below.


Ingredient matches for Belepar



Benserazide

Benserazide is reported as an ingredient of Belepar in the following countries:


  • Poland

Levodopa

Levodopa is reported as an ingredient of Belepar in the following countries:


  • Poland

International Drug Name Search

Wednesday, 23 September 2009

Bosentan




In the US, Bosentan (bosentan systemic) is a member of the drug class agents for pulmonary hypertension and is used to treat Pulmonary Arterial Hypertension.

US matches:

  • Bosentan

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

C02K,C02KX01

CAS registry number (Chemical Abstracts Service)

0147536-97-8

Chemical Formula

C27-H29-N5-O6-S

Molecular Weight

551

Therapeutic Categories

Antihypertensive agent

Endothelin antagonist

Chemical Names

Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl] (USAN)

p-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide (WHO)

Foreign Names

  • Bosentanum (Latin)
  • Bosentan (German)
  • Bosentan (French)
  • Bosentán (Spanish)

Generic Names

  • Bosentan (OS: BAN, USAN)
  • Ro 47-0203 (IS: Roche)
  • Ro 47-0203/029 (IS: Roche)

Brand Names

  • Tracleer
    Actelion, Germany; Actelion, Denmark; Actelion, Slovenia; Actelion, Thailand; Actelion, Turkey; Excelsior, Taiwan; Actelion, Austria; Actelion, Australia; Actelion, Belgium; Actelion, Canada; Actelion, Switzerland; Actelion, Czech Republic; Actelion, Spain; Actelion, France; Actelion, United Kingdom; Actelion, Hungary; Actelion, Ireland; Actelion, Israel; Actelion, Iceland; Actelion, Italy; Actelion, Japan; Actelion, Luxembourg; Actelion, Netherlands; Actelion, Norway; Actelion, Singapore; Actelion, Slovakia; Actelion, United States; Actelion Pharmaceuticals, Sweden; Healthcare Logistics, New Zealand; Swedish Orphan, Finland

International Drug Name Search

Glossary

BANBritish Approved Name
ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.